Genomic Health: Genomic Health Delivers Online Perspective
REDWOOD CITY, CA--(Marketwire - July 31, 2009) - As a leader in the field of personalized medicine, [ Genomic Health ] Inc. (
[ Genomic Health ] plans to use the column to weigh in on healthcare topics that are generating debate in Washington, on Wall Street and within the medical community. "We're looking forward to generating an Op-Ed type discussion," says [ Kim Popovits ], President and CEO of Genomic Health. "Whether it's related to diagnostics, cancer treatment issues or a breakthrough technology -- we think it's important for Genomic Health to have a voice in these online conversations and encourage readers to visit [ our website ] to learn more about the promise of [ personalized medicine." ]
About Genomic Health
[ Genomic Health ], Inc. (
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and potential delays associated with commercialization of a new test; the risks and uncertainties associated with the regulation of the company's tests; the applicability of clinical study results to actual outcomes; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
Links to third-party websites or pages are provided for convenience only. Each website is subject to its own terms of use, and we encourage you to consult these policy statements. Genomic Health has no control over third party sites and does not endorse or recommend these sites, and expressly disclaims any responsibility for the accuracy of content or opinions set forth in any third party website or your use of that information. In addition, Genomic Health disclaims all liability arising out of allegations that third party content infringes the intellectual property rights of any person. Information in this release should not be considered medical advice. Patients should consult their doctor to determine the appropriate treatment decision for their individual disease.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.